Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,933 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Familial Alzheimer Disease Clear all
Completed Not applicable Interventional

The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment

NCT04073628
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Albany, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Completed No phase listed Observational

Goal Attainment Scaling (GAS) Sub-Study

NCT06484426
View directory record Official record
Conditions
Alzheimer's Disease in Down Syndrome
Interventions
Not listed
Lead sponsor
LuMind IDSC Foundation
Other
Eligibility
35 Years and older
Enrollment
46 participants
Timeline
2021 – 2024
U.S. locations
5
States / cities
San Diego, California • Park Ridge, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Lipitor as a Treatment for Alzheimer's Disease

NCT00024531
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Atorvastatin calcium
Drug
Lead sponsor
Institute for the Study of Aging (ISOA)
Other
Eligibility
50 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 9, 2006 · Synced Oct 18, 2026, 5:23 PM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

NCT04270175
View directory record Official record
Conditions
Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
Interventions
Daratumumab SC, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

NCT00812565
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, octagam 10%
Drug · Biological
Lead sponsor
Octapharma
Industry
Eligibility
50 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hoboken, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 18, 2026, 5:23 PM EDT
Withdrawn Phase 1 Interventional

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

NCT03316898
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AGN-242071, Placebo, Donepezil, Memantine
Drug
Lead sponsor
Allergan
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Costa Mesa, California • Irvine, California • Lemon Grove, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 18, 2026, 5:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616
View directory record Official record
Conditions
Alzheimer Disease
Interventions
JNJ-64042056, Placebo
Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
55 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Murrieta, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Terminated Phase 3 Interventional Results available

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

NCT02284906
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
28
States / cities
Phoenix, Arizona • Sun City, Arizona • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Care of Persons With Dementia in Their Environments (COPE) in Programs of All-Inclusive Care of the Elderly (PACE)

NCT04165213
View directory record Official record
Conditions
Frontotemporal Dementia, Dementia, Multi-Infarct Dementia, Vascular Dementia, Mixed Dementia, Alzheimer Disease, Lewy Body Disease, Pick Disease, Neurocognitive Disorders
Interventions
Care of Older Persons in their Environment (COPE) online module training
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 100 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Innovations in Dementia Empowerment and Action

NCT03550131
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment, Parkinson Disease Dementia, Lewy Body Dementia, Vascular Dementia
Interventions
Innovations in Dementia Empowerment and Action (IDEA), Reducing Disabilities in Alzheimer's Disease (RDAD)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
322 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 18, 2026, 5:23 PM EDT
Not listed No phase listed Observational

Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease

NCT01841905
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Observational Study
Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2

NCT05837819
View directory record Official record
Conditions
Alzheimer's Disease, Sleep Disturbance
Interventions
Active Lighting Intervention, Control Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
65 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Albany, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 2Phase 3 Interventional

Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

NCT00065767
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Raloxifene
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 18, 2026, 5:23 PM EDT
Not yet recruiting Phase 2 Interventional

Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

NCT07781657
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RO7568282, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Laurelton, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional

A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00087724
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
FK962
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
72
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Hypnosis for Sleep Quality in Caregivers of Individuals With Alzheimer's Disease

NCT04779866
View directory record Official record
Conditions
Poor Quality Sleep, Caregiver Stress, Alzheimer's Disease (Incl Subtypes)
Interventions
Self-Administered Hypnosis, Self-Administered White Noise Hypnosis
Behavioral
Lead sponsor
Baylor University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's

NCT00980785
View directory record Official record
Conditions
Alzheimer's Disease, Hypertension
Interventions
Ramipril, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects

NCT02061878
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bexarotene, Placebo
Drug
Lead sponsor
ReXceptor, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 18, 2026, 5:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bilateral Brain Dynamics in Cognition and Aging

NCT03224988
View directory record Official record
Conditions
Alzheimer Disease, Aging, MCI
Interventions
TMS
Device
Lead sponsor
Duke University
Other
Eligibility
60 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Not applicable Interventional

7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD

NCT05596994
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Lighting Intervention Therapy, Sham LIT
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00733642
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04360365 1 mg/kg, PF-04360365 3 mg/kg, PF-04360365 5 mg/kg, PF-04360365 10 mg/kg
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Glendale, California • Eatontown, New Jersey • Oakhurst, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Oct 18, 2026, 5:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Study of Caregiver Connections Via Technology in Dementia

NCT05779839
View directory record Official record
Conditions
Caregiver Stress, Dementia, Alzheimer Disease, Lewy Body Dementia, Parkinson Disease Dementia, Frontotemporal Dementia
Interventions
Algorithm, Random Match
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00498602
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
27
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Effect of NeuroAD on the Cognitive Function of Alzheimer Patients

NCT01825330
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TMS and cognitive stimulation, sham
Device
Lead sponsor
Neuronix Ltd
Industry
Eligibility
60 Years to 90 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Sun City, Arizona • Costa Mesa, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 18, 2026, 5:23 PM EDT